Results 141 to 150 of about 12,433,729 (358)
Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia+17 more
wiley +1 more source
Summary: Early warning of regime switching in a complex financial system is a critical and challenging issue in risk management. Previous research has examined regime switching through analyzing the fluctuation features in a single point in time series ...
Sufang An, Xiangyun Gao, Feng An, Tao Wu
doaj
Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley +1 more source
An Experimental Study of the Merits of Extensive and Intensive Reading in the Social Sciences [PDF]
Carter V. Good
openalex +1 more source
Clinical significance of stratifying prostate cancer patients through specific circulating genes
We tested a specific panel of genes representative of luminal, neuroendocrine and stem‐like cells in the blood of prostate cancer patients, showing predictive value from diagnosis to late stages of disease. This approach allows monitoring of treatment responses and outcomes at specific time points in trajectories.
Seta Derderian+12 more
wiley +1 more source
MET variants in the N‐lobe of the kinase domain, found in hereditary papillary renal cell carcinoma, require ligand stimulation to promote cell transformation, in contrast to other RTK variants. This suggests that HGF expression in the microenvironment is important for tumor growth in such patients. Their sensitivity to MET inhibitors opens the way for
Célia Guérin+14 more
wiley +1 more source